

Alpha-2C Adrenergic Receptor Antibody

Alpha2C Adrenergic Antibody, Clone S330A-80 Catalog # ASM10269

Specification

Alpha-2C Adrenergic Receptor Antibody - Product Information

Application WB
Primary Accession P18825
Other Accession NP_000674.2
Host Mouse
Isotype IgG1

Reactivity Human, Mouse Clonality Monoclonal

Description

Mouse Anti-Human Alpha-2C Adrenergic Receptor Monoclonal IgG1

Target/Specificity

Detects 50kDa or larger (possibly due to dimerization). Does not cross-react with other adrenergic receptors.

Other Names

Adra 2c Antibody, Alpha-2CAR Antibody, ADRA2C Antibody, ADRA2L2 Antibody, ADRARL2 Antibody, Alpha 2CAR Antibody, alpha2 AR C4 Antibody, alpha2 C4 Antibody, alpha2C Antibody, ALPHA2CAR Antibody, Alpha-2 adrenergic receptor subtype C4 Antibody, Alpha-2C adrenoreceptor Antibody, Adrenergic alpha 2C receptor Antibody, Alpha 2C adrenoceptor Antibody, Alpha 2C adrenoceptor Antibody, Alpha 2C adrenoceptor Antibody, Alpha-2-adrenergic receptor Antibody, renal type Antibody, alpha2cii-adrenergic receptor Antibody, Subtype alpha2 C4 Antibody

Immunogen

Synthetic peptide amino acids 442- 462 (QDFRRSFKHILFRRRRRGFRQ, cytoplasmic C-terminus) of human Alpha-2C adrenergic receptor

Purification

Protein G Purified

Storage -20°C

Storage Buffer

PBS pH7.4, 50% glycerol, 0.09% sodium azide

Shipping Temperature

Blue Ice or 4ºC

Certificate of Analysis

 $1 \mu g/ml$ of SMC-435 was sufficient for detection of Alpha2C Adrenergic Receptor in 20 μg of COS cells transiently transfected with HA-tagged Alpha- lysate and assayed by colorimetric immunoblot analysis using goat anti-mouse IgG:HRP as the secondary antibody.

Cellular Localization

Cell Membrane


Alpha-2C Adrenergic Receptor Antibody - Protocols




Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Alpha-2C Adrenergic Receptor Antibody - Images



Immunocytochemistry/Immunofluorescence analysis using Mouse Anti-Alpha-2C Adrenergic Receptor Monoclonal Antibody, Clone S330A-80 (ASM10269). Tissue: Neuroblastoma cell line (SK-N-BE). Species: Human. Fixation: 4% Formaldehyde for 15 min at RT. Primary Antibody: Mouse Anti-Alpha-2C Adrenergic Receptor Monoclonal Antibody (ASM10269) at 1:100 for 60 min at RT. Secondary Antibody: Goat Anti-Mouse ATTO 488 at 1:100 for 60 min at RT. Counterstain: Phalloidin Texas Red F-Actin stain; DAPI (blue) nuclear stain at 1:1000, 1:5000 for 60min RT, 5min RT. Localization: Cell Membrane, Nucleus. Magnification: 60X. (A) DAPI (blue) nuclear stain (B) Phalloidin Texas Red F-Actin stain (C) Alpha-2C Adrenergic Receptor Antibody (D) Composite.





Western Blot analysis of Monkey COS cells transfected with HA-tagged Alpha-2C showing detection of ~ 50 kDa Alpha-2C Adrenergic Receptor protein using Mouse Anti-Alpha-2C Adrenergic Receptor Monoclonal Antibody, Clone S330A-80 (ASM10269). Lane 1: Molecular Weight Ladder. Lane 2: Monkey COS cells transfected with HA-tagged Alpha-2C. Load: 15 μ g. Block: 2% BSA and 2% Skim Milk in 1X TBST. Primary Antibody: Mouse Anti-Alpha-2C Adrenergic Receptor Monoclonal Antibody (ASM10269) at 1:200 for 16 hours at 4°C. Secondary Antibody: Goat Anti-Mouse IgG: HRP at 1:1000 for 1 hour RT. Color Development: ECL solution for 6 min in RT. Predicted/Observed Size: ~ 50 kDa.

Alpha-2C Adrenergic Receptor Antibody - Background

The alpha 2C Adrenergic Receptor controls the release of neurotransmitter from central adrenergic neurons and from sympathetic nerves in the heart. This receptor also plays a role in cognitive and behavioral function. Two variants are produced by alternative splicing. Alpha 2C Adrenergic Receptor has been reported extensively in the brain. Blood, corpus cavermosum, kidney, and heart tissues have also been reported to express the protein.

Alpha-2C Adrenergic Receptor Antibody - References

- 1. Filipeanu C.M., et al. (2011) Biochim Biophys Acta. 1813: 346-357.
- 2. Powe D.G., et al. (2011) Breast Cancer Res Treat. 130: 457-463.